Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeCLINICAL TRIALS, STUDIES, DATAPROCEPT BioRobotics Announces Three-Year Follow-Up Data Confirming Sustained Efficacy, Superior Safety of...

PROCEPT BioRobotics Announces Three-Year Follow-Up Data Confirming Sustained Efficacy, Superior Safety of Aquablation® Therapy for Benign Prostatic Hyperplasia

Reza Zadno, president and CEO of PROCEPT BioRobotics notes, “The publication of these three-year study results is a very important milestone for PROCEPT BioRobotics, as it provides compelling evidence of the long-term durability and safety of Aquablation therapy.”  He added, “We are thrilled to see the results and agree with the study co-authors, who concluded that autonomous robotic technology may ultimately offer standardization that improves overall outcomes for all urologists and their patients.”

The AquaBeam Robotic System is the first FDA-granted surgical robot for the autonomous removal of prostate tissue in males suffering from benign prostatic hyperplasia. In the study, 181 patients with prostates sized 30 to 80 cc were randomized to either Aquablation therapy or TURP. At three years, investigators found that improvements in IPSS scores, Qmax, PVR, and PSA were statistically similar across groups, but noted superior symptom improvement in the Aquablation therapy arm for patients with prostates larger than 50cc. Moreover, changes in MSHQ-EjD and MSHQ bother scores were significantly lower in the Aquablation therapy group. Additionally, no patients required surgical retreatments for BPH beyond 20 months.

“The high-quality results of this three-year study build on a large foundation of clinical data supporting the safety and efficacy of Aquablation therapy for the treatment of BPH,” said Study Co-author Peter Gilling, M.D, Professor of Surgery at the University of Auckland, Bay of Plenty Clinical School Tauranga. “Unlike any other BPH treatment currently available, Aquablation therapy integrates image guidance and robotic execution, and I believe that Aquablation has the potential to become a new standard of care for urologists and their patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy